idh mutations

0:01:36

IDH Mutations in Cancer

0:11:50

The Patient is In: Introduction to IDH-mutant cancers with Matthew Vander Heiden

0:05:16

IDH1 mutation, histology, and treatment of tissue metabolites in diffuse glioma

0:02:23

Vorasidenib in IDH-Mutant Glioma | NEJM

0:06:14

IDH Mutations in AML

0:01:14

The impact of IDH mutations in MDS & evaluating the role of IDH inhibitors

0:02:08

The impact of IDH mutations on the outcomes of patients with AML & inhibitors under investigation

0:02:57

Targeting IDH mutations for the treatment of AML

0:01:02

How Do IDH Mutations Cause Tumors?

1:01:30

From Mutation to Treatment: Understanding IDH Inhibitors

0:02:53

The prognostic impact of IDH mutations and the role of IDH inhibitors in MDS

0:04:51

The impact of IDH mutated clones in NPM1+ AML

0:01:11

Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?

0:04:10

Explore IDH Mutations

0:02:05

IDH Inhibitors for Cholangiocarcinoma

0:02:31

IDH mutations in AML treated with venetoclax

0:01:21

Addressing treatment options for IDH-mutant gliomas

0:31:39

Glioblastoma/Grade 4 Astrocytoma: Personalized Medicine & Targeted Therapy

0:04:20

Enasidenib’s Role in IDH-Mutant Acute Myeloid Leukemia

0:02:23

IDH-Mutation bei Gliomen | Strahlentherapie Prof. Hilke Vorwerk

0:04:38

Curtis Andrew Lachowiez: Ivosidenib + Venetoclax and Azacitidine in IDH-Mutated Myeloid Malignancies

0:01:03

IDH mutations in AML

0:18:21

New Treatment for IDH mt Gliomas

0:04:46

IDH-specific vaccine for high-grade gliomas